Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
Biomolecules · 07.06.2023 · 13 (6) · 954
DOI: 10.3390/biom13060954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 07.06.2023. Verfasst von Maja Hanić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genos Glycoscience Research Laboratory, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: Crohn Disease, Biological Products. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust, CORE (renamed Guts UK in 2018), the research charity of the British Society of Gastroenterology.
Abstract (Originalsprache)
Crohn’s disease (CD) is a chronic inflammation of the digestive tract that significantly impairs patients’ quality of life and well-being. Anti-TNF biologicals revolutionised the treatment of CD, yet many patients do not adequately respond to such therapy. Previous studies have demonstrated a pro-inflammatory pattern in the composition of CD patients’ immunoglobulin G (IgG) N-glycome compared to healthy individuals. Here, we utilised the high-throughput UHPLC method for N-glycan analysis to explore the longitudinal effect of the anti-TNF drugs infliximab and adalimumab on N-glycome composition of total serum IgG in 198 patients, as well as the predictive potential of IgG N-glycans at baseline to detect primary non-responders to anti-TNF therapy in 1315 patients. We discovered a significant decrease in IgG agalactosylation and an increase in monogalactosylation, digalactosylation and sialylation during the 14 weeks of anti-TNF treatment, regardless of therapy response, all of which suggested a diminished inflammatory environment in CD patients treated with anti-TNF therapy. Furthermore, we observed that IgG N-glycome might contain certain information regarding the anti-TNF therapy outcome before initiating the treatment. However, it is impossible to predict future primary non-responders to anti-TNF therapy based solely on IgG N-glycome composition at baseline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genos Glycoscience Research Laboratory, 10000 Zagreb, Croatia.
- Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter EX4 4SB, UK.
- Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia.
ORCID-Profile: Maja Hanić, Helena Deriš, Claire Bewshea, Irena Trbojević-Akmačić
Förderung
- Medical Research Council
- Wellcome Trust
- CORE (renamed Guts UK in 2018), the research charity of the British Society of Gastroenterology
- AbbVie Inc., North Chicago, IL, USA
- Merck Sharp & Dohme Ltd., London, UK
- NAPP Pharmaceuticals Ltd., Cambridge, UK
- Pfizer Ltd., New York, NY, USA
- Celltrion Healthcare, Incheon, South Korea
Zitieren
APA
Hanić, M., Vučković, F., Deriš, H., Bewshea, C., Lin, S., Goodhand, J. R., Ahmad, T., Trbojević-Akmačić, I., Kennedy, N. A., Lauc, G., & PANTS Consortium (2023). Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease. Biomolecules, 13(6), 954. https://doi.org/10.3390/biom13060954
Vancouver
Hanić M, Vučković F, Deriš H, Bewshea C, Lin S, Goodhand JR, et al. Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease. Biomolecules. 2023;13(6):954. doi:10.3390/biom13060954
BibTeX
@article{Hani2023,
author = {Hanić, Maja and Vučković, Frano and Deriš, Helena and Bewshea, Claire and Lin, Simeng and Goodhand, James R and Ahmad, Tariq and Trbojević-Akmačić, Irena and Kennedy, Nicholas A and Lauc, Gordan and PANTS Consortium, PANTS Consortium},
title = {Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {6},
pages = {954},
doi = {10.3390/biom13060954}
}
EUVIMED